Trial Profile
Zoledronic acid injection (Aclasta) prevention of osteoporosis in clinical studies in patients with total knee replacement bone loss in the early postoperative
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2016
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 20 Aug 2016 Status changed from not yet recruiting to completed.
- 18 Mar 2014 New trial record